"Ingredients to produce the jabs will arrive from plants based in Europe, while the manufacturing of finished doses will start in 2022," the companies said.
The companies plan that at “full operation capacity” the annual production of Biovac will reach 100 million doses annually, to be distributed to AU member states.
The announcement comes as just 1.5 percent of people in Africa are fully vaccinated, compared with 43.7 percent in the European Union and nearly 50 percent in the United States, according to Our World in Data.
India and South Africa have been pushing a proposal to temporarily lift intellectual property (IP) rights on vaccines to boost global manufacturing capacity, and unequal distribution has been a source of debate for months at the World Trade Organization.
Pfizer says a South African firm will begin producing the Pfizer/BioNTech COVID-19 vaccine, the first time that the vaccine will be produced in Africa. The Biovac Institute in Cape Town will manufacture the vaccine for distribution across the continent. https://t.co/gZJrmNH1f4